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Abstract
Preimplantation embryos of mammals are enclosed by a translucent layer called zona pel-
lucida (ZP), which is composed of glycoproteins. ZP is important for protecting against 
infection by virus and bacteria, and to prevent attachment of embryos to the oviductal 
epithelia. Due to the presence of ZP, it has been difficult to transfect preimplantation 
embryos existing within the oviductal lumen, with exogenous nucleic acids, such as DNA 
and mRNA. However, intraoviductal instillation of nucleic acids, and subsequent in vivo 
electroporation in pregnant females, enables transfection of these embryos, leading to 
the production of gene-modified animals. This new method for production of genetically 
modified animals does not require any ex vivo handling of embryos, which has been essen-
tial for traditional transgenesis. In this article, we describe recent advances in the in vivo 
transfection of preimplantation mammalian embryos, and also the possibility of simple 
transfection of these embryos through intraoviductal instillation of a solution, alone.
Keywords: genome editing, GONAD, in vivo gene transfer, oviduct, preimplantation 
embryos
1. Introduction
Ex vivo handling of early embryos, which includes embryo collection from pregnant animals, 
introduction of genetic material or genetically modified embryonic stem (ES) cells into the 
isolated embryos, and egg transfer (ET) to a recipient female reproductive tract, has been con-
sidered essential for production of transgenic and knock out (KO) animals [1, 2]. The recently 
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developed genome editing technology, as exemplified by CRISPR/Cas9 system, requires ex 
vivo handling of embryos, namely, microinjection of the genome editing component into the 
zygote, or in vitro electroporation (EP) in the presence of those materials, embryo culture, 
and subsequent ET [3–7]. Unfortunately, such ex vivo handling of early embryos requires an 
expensive manipulator, special technicians to handle this machine and perform ET, and prep-
aration of recipient females for ET, all of which are sometimes time-consuming and laborious. 
If this ex vivo handling of embryos is omitted, embryo manipulation, including production of 
genome-edited animals, would become more convenient.
Preimplantation embryos present within the oviductal lumen would be the most favorable 
targets for genetic manipulation, since the oviducts themselves can be easily exposed out-
side the individual, under anesthesia, and manipulation within this organ would be possible 
under observation, using a dissecting microscope. Genetic material can be introduced into 
zygotes or cleaving embryos, floating in the oviductal lumen, by inserting a glass pipette 
through the oviductal wall, and introducing genetic material successfully into these embryos 
by penetrating the zona pellucida (ZP). If this event occurs, in situ production of genetically 
modified embryos (animals) would be possible.
The ZP is a multilayered porous matrix of glycoproteins that envelopes mammalian oocytes and 
preimplantation embryos, protecting them from environmental insults, including viral infec-
tion, and injury by chemical or physical substances [8]. Therefore, it has been difficult to trans-
fect mammalian oocytes and preimplantation embryos, with the usual transfection methods that 
have proven useful for somatic cells. Early attempts at gene delivery to preimplantation embryos 
involved the transfection of ZP-free embryos. However, such embryos are vulnerable, adhesive, 
and easily damaged [9]. The most commonly method used for penetration of ZP for gene delivery 
is the pronuclear microinjection using purified DNA [10], or the microinjection of viral elements 
into the perivitelline space, between ZP and the zygotes [11]. Furthermore, it is possible to transfect 
mouse fertilized eggs with lentiviral vectors, via laser perforation of ZP [12]. In vitro EP was found to 
be effective for incorporation of plasmid DNA and morpholino, into mouse fertilized eggs, after ZP 
was weakened by a brief treatment with acidic Tyrode’s solution [13–15]. This treatment allowed 
the enhanced uptake of exogenous DNA, and protected the embryos from electroporation dam-
age. Notably, previous reports clearly indicate the need for penetrating the ZP for manipulation 
of early embryos, and also the ex vivo handling of embryos prior to ET. Thus, it may be desirable 
to perform gene delivery to preimplantation embryos, without handling the embryos ex vivo, and 
if possible, to employ substances that will allow direct gene delivery through penetration of ZP.
In the present article, we first discuss studies that have reported successful delivery of sub-
stances to ZP-enclosed embryos in vitro, followed by reports on in vivo transfer of substances 
into ZP-enclosed preimplantation embryos, after intraoviductal instillation. Lastly, we describe 
the recent advances in in situ genome editing of embryos, present in the oviductal lumen.
2. Transfer of exogenous substances into ZP intact embryos via 
simple incubation
As mentioned previously, it may be possible to perform gene delivery to embryos if a substance 
capable of penetrating ZP is used in combination with nucleic acids. For example, Ivanova et al. 
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[16] demonstrated that when ZP intact preimplantation embryos from mice and rabbits were incu-
bated in a medium containing DNA-carrying constructs with insulin as an internalizable ligand, 
(insulin-polylysine)-DNA and (insulin polylysine)-DNA-(streptavidin-polylysine)-(biotinylated 
adenovirus), the constructs penetrated the ZP and accumulated within each blastomere. 
Southern blot hybridization revealed chromosomal integration of transgenes in mid-gestational 
fetuses and in a newborn. The ligand-mediated gene delivery to early embryos can be explained 
by the following mechanism. Insulin provides delivery inside the cell, while adenoviruses ensure 
release from the endosomes. They called this type of gene delivery “receptor-mediated gene 
transfer”. According to the authors, the construct containing DNA and insulin, penetrates inside, 
to accumulate in the peri-nuclear space of the embryos. Munk et al. [17] demonstrated that mul-
tiwall carbon nanotubes (MWNTs) could cross the ZP to help the delivery of plasmid DNA into 
bovine embryos in vitro. Exposure of embryos to MWNTs did not affect their viability and gene 
expression. Interestingly, Joo et al. [18] recently developed a hydrophilic, Cy5.5-labeled organic 
compound called “VisuFect”. When VisuFect is conjugated with poly(A) oligo, this complex suc-
cessfully penetrates the ZP of the fertilized eggs of various species, including zebrafish, mice, and 
pigs, suggesting that VisuFect can be used to deliver genome-editing nucleic acids to ZP intact 
embryos to generate genetically modified animals. Unfortunately, VisuFect can deliver oligo-
nucleotides to embryos, but not larger molecules, such as the plasmid DNA. Probably, genome 
editing in embryos derived from Cas9-expressing transgenic (Tg) mice [19–25] may be possible 
when VisuFect is used in combination with a smaller molecule such as guide (g) RNA.
As mentioned previously, EP enables the delivery of exogenous substances to somatic cells 
and ZP-enclosed embryos. Grabarek et al. [13] was the first to demonstrate that nucleic acids 
can be efficiently delivered to isolated embryos (oocytes and zygotes) by EP. Recently, Kaneko 
et al. [26] first demonstrated successful induction of genome editing of the target locus in 
rat embryos, when they were electroporated in vitro in the presence of CRISPR/Cas9-related 
components (Cas9 mRNA + gRNA). In this case, there was no need to weaken ZP, as Grabarek 
et al. [13] demonstrated. Since this report, similar success in the production of genome-edited 
animals has been reported in mice and pigs [27–29].
3. Intraoviductal instillation of a solution
Delivery of liposomally encapsulated DNA directly into the oviductal lumen was first reported 
by Esponda’s group [30, 31]. The purpose of their study was to transfect epithelial cells lining 
the oviductal lumen, not to deliver genetic materials to preimplantation embryos floating 
in the oviductal lumen. They found that ~6% of oviductal epithelial cells were successfully 
transfected. Sato [32] injected a solution containing plasmid DNA [conferring enhanced green 
fluorescent protein (EGFP) expression] into the oviductal lumen of pregnant female mice on 
Day 0.4 (~11:00 h; corresponding to early zygotes; the day when the vaginal plugs are detected 
is designated as Day 0 of pregnancy), and then performed in vivo EP of an entire oviduct, in an 
attempt to transfect zygotes with the exogenous DNA. Unfortunately, the attempt to transfect 
zygotes failed; only a cellular remnant, probably derived from a part of the zygotes, was 
found to be fluorescent. In contrast, a maximum of 43% of oviductal epithelial cells facing the 
oviductal lumen, were fluorescent. It was speculated that the failure of gene delivery to the 
zygotes may be because the cumulus cells surrounding the zygotes function as a barrier [32].
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Figure 1 represents a schematic illustration of the structure of murine oviduct and ovary, on 
different days of pregnancy; Days 0.4 (Figure 1a), 0.7 (~16:00 h; corresponding to late zygotes; 
Figure 1b) and 1.4 (~1d, 11:00 h; corresponding to 2-cell embryos; Figure 1c), are illustrated. 
After mating with males, ovulated oocytes, tightly surrounded by cumulus cells, are trans-
ferred to the specific site of the oviduct - the ampulla- following which fertilization occurs at 
Figure 1. Procedure for the intraoviductal instillation of a solution. a-c: schematic illustration of ovary/oviduct/uterus 
of females at days 0.4 (a), 0.7 (b) and 1.4 (c) of pregnancy. d, e: schematic illustration of the moment before (d) and 
during (e) the intraoviductal instillation of a solution through oviductal wall. f, g: Oviduct at day 0.4 before (f) and 
after (g) intraoviductal instillation of trypan blue-containing solution. Arrows indicate the site through which a glass 
micropipette was inserted into the oviductal lumen.
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Figure 2. Intraoviductal instillation of a solution containing DAPI and trypan blue. a, b, two-cell embryos isolated from a 
female 1 day after the intraoviductal instillation of a solution containing DAPI and trypan blue on day 0.4 of pregnancy. 
Note the presence of bright DAPI-derived fluorescence in the nuclei of 2-cell embryos. Arrow indicates aggregates of 
trypan blue, which might have formed after introduction into the oviductal lumen. Bar = 100 μm. c, d, two-cell embryos 
isolated from a female one day after the intraoviductal instillation of a solution containing trypan blue alone, on day 0.4 
of pregnancy. No fluorescence is detected in the nuclei. Bar = 100 μm. e, f, DAPI-derived fluorescence in the squashed 
oviduct from which 2-cell embryos [shown in (a) and (b)] were isolated. Note bright fluorescence in ampulla (arrows), 
and its neighboring segment of the oviduct. Box indicates the oviductal segment near isthmus. Bar = 250 μm. g, h: DAPI-
derived fluorescence in the squashed oviduct from which the 2-cell embryos [shown in (c) and (d)] were isolated. No 
fluorescence is detected throughout the oviduct, including ampulla (arrows). Box indicates the oviductal segment near 
isthmus. Bar = 250 μm. a, c, e, g: Photographed under light; b, d, f, h: Photographed under UV and light.
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this site. On Day 0.4, zygotes (fertilized eggs) are still enclosed by cumulus cells and exist at 
the ampulla. On Day 0.7, zygotes are still present at the ampulla, but the ampulla itself, exhib-
its shrinkage and detachment of cumulus cells from the zygote. On Day 1.4, zygotes cleave 
to form 2-cell embryos, and are present at the ampulla or the oviductal segment between the 
ampulla and the isthmus.
In Figure a schematic illustration of the moments before (Figure 1d) and during (Figure 1e) 
intraoviductal instillation of a solution is provided. Sato et al. [33] injected a solution contain-
ing Hoechst33342 dye, frequently used for vital nuclear staining, into the oviductal lumen of 
pregnant females at Day 0.4. One day after the surgery, 2-cell embryos were collected from 
the oviducts for checking the incorporation of the dye in their nuclei. They observed that all 
the collected embryos had fluorescent nuclei. This means that the dye injected into the ovi-
ductal lumen penetrates the ZP, enters the zygotes, and binds to their nuclear DNA. Here, we 
examined whether another dye 4′, 6-diamidino-2-phenylindole (DAPI), also used for staining 
of nuclei, can also bind to nuclear DNA of zygotes in situ. About 2 μL of a solution contain-
ing 1 μg/μL of DAPI and 0.05% trypan blue (used for monitoring successful injection) was 
injected into the oviductal lumen by piercing the oviductal wall, between the ampulla and the 
infundibulum (arrows in Figure 1e and f) of pregnant B6C3F1 (hybrid between C57BL/6 and 
C3H/He) females on Day 0.4. Successful instillation of a solution can be clearly visualized by 
the presence of blue dye inside the oviduct (arrowhead in Figure 1g). As control, trypan blue 
alone was similarly injected. When 2-cell embryos are collected from the treated females for 
inspection of fluorescence, all the collected embryos (6/6 tested) from DAPI-injected females 
had fluorescent nuclei (Figure 2a and b); in contrast, the control embryos did not have fluo-
rescent nuclei (Figure 2c,d). Furthermore, inspection of DAPI-derived fluorescence in the 
squashed oviduct revealed the presence of fluorescence in epithelial cells of ampulla and its 
neighboring oviductal segment (Figure 2e and f), but no evident fluorescence in the distal 
segment of the oviduct, near the isthmus (boxed areas in Figure 2e and f), suggesting that 
DAPI introduced into the ampulla, might not have been transferred to the oviductal segment 
near the uterus in a day, after the instillation. The control oviduct never fluoresced (Figure 2g 
and h). Thus, DAPI introduced intraoviductally can penetrate ZP-enclosed zygotes and ovi-
ductal epithelia facing oviductal lumen.
4. Gene delivery into preimplantation embryos in vivo
To our knowledge, successful gene delivery into preimplantation embryos in vivo was first 
reported by Sato et al. [33], who demonstrated the intraoviductal instillation of a solution 
containing plasmid DNA (conferring EGFP expression) and trypan blue using B6C3F1 
females on Day 1.4 of pregnancy (corresponding to 2-cell stage). Subsequently, in vivo EP into 
an entire oviduct was performed using a square-wave pulse generator, T-820 electropora-
tor (BTX Genetronics Inc., San Diego, CA, USA), under the conditions of eight square-wave 
pulses, with a pulse duration of 50 ms, and an electric field intensity of 50 V. One day after the 
surgery, 8-cell embryos were collected for checking EGFP-derived fluorescence. About 33% 
of embryos exhibited fluorescence, although its intensity varied among embryos. However, 
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when the same procedure was later applied to 2-cell stage embryos using a different elec-
troporator (NEPA21; NEPA GENE Co., Chiba, Japan), all the collected embryos failed to 
fluoresce (Sato et al., unpublished results). In this case, the ZP appears to act as a critical bar-
rier, preventing substance penetration. In other words, ZP may allow penetration of smaller 
molecules such as gRNA, but not of large molecules like plasmid DNA. In this context, careful 
monitoring of EP conditions may be required when larger sized molecules are intended to be 
introduced into early embryos in vivo.
Takahashi et al. [34] employed the method of Sato et al. [33] to induce genome editing in the 
target gene (EGFP cDNA) in EGFP-expressing Tg 2-cell embryos in situ, through intraovi-
ductal injection of a solution containing CRISPR/Cas9-related components (Cas9 mRNA + 
gRNA targeted to EGFP cDNA). Inspection of fluorescence under a fluorescence microscope 
demonstrated that 33% (2/6) of the resultant mid-gestational fetuses exhibited complete loss 
of EGFP-derived fluorescence, and 33% (2/6) exhibited reduced fluorescence. Sequencing 
analysis of genomic DNA isolated from these fetuses revealed that no mosaic mutations were 
detectable in the samples showing complete loss of fluorescence. Mosaic mutations were also 
detectable in the samples showing reduced fluorescence. Based on these findings, it was found 
that intraoviductal instillation of a solution containing CRISPR/Cas9-related components, and 
subsequent in vivo EP, enables genome editing in a whole embryo. Thus, Takahashi et al. [34] 
named this technology “Genome editing via Oviductal Nucleic Acids Delivery (GONAD)”.
As mentioned above, GONAD on Day 1.5 results in production of individuals with highly 
frequent mosaic mutations. Genome editing at 2-cell embryo stage, appears to be the major 
cause of this problem. To circumvent the issue of mosaic mutations, performing GONAD 
on Day 0.7, a stage corresponding to late 1-cell embryos, from which cumulus cells begin 
to detach (see Figure 1b), was considered. Ohtsuka et al. [35] examined whether embryos 
at this stage are suitable for GONAD by injecting a solution containing EGFP mRNA (1 μg/
μL) and trypan blue (0.05%) into the lumen of an oviduct of pregnant ICR females, since 
EGFP-derived fluorescence can be easily monitored under a fluorescence microscope. Two 
days after GONAD, 8-cell embryos were isolated from the oviducts of the GONAD-treated 
females, and checked for EGFP-derived fluorescence; several of the collected 2-cell embryos 
were found to be fluorescent. Notably, no or less biased fluorescence was evident in each blas-
tomere among the fluorescent embryos, suggesting low mosaicism in the treated embryos.
5. Genome editing in preimplantation embryos after performing 
GONAD on day 0.7
Next, we tested whether GONAD can indeed induce specific mutations on the endogenous 
target locus in late 1-cell embryos. We chose α-1, 3-galactosyltransferase (α-GalT) gene 
(GAAT1) as a target gene to be knocked out. α-GalT is a key enzyme, capable of synthesizing 
the cell-surface glycoprotein, called α-Gal epitope that is expressed in all mammals, except 
humans and Old-Word monkeys [36, 37]. Complete KO of GAAT1 leads to loss of α-Gal 
epitope expression, which can be easily monitored by staining with α-Gal epitope-specific 
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lectin called BS-I-B
4
 (IB4) [38, 39]. Indeed, cloned porcine blastocysts, after reconstitution with 
GAAT1 KO nuclei, lost the reactivity against fluorescence-labeled IB4. However, residual 
amounts of α-Gal epitope, which may have been derived from maternally accumulated prod-
ucts of α-GalT, were occasionally recognized by the α-Gal epitope-specific lectin in the cloned 
blastocysts [40].
We designed gRNA (5′-GAGAAAATAATGAATGTCAA-3′) for targeting exon 4 of murine 
GAAT1. A part of the gRNA was synthesized by Integrated DNA Technologies, Inc. (IDT; 
Coralville, Iowa, USA) as Alt-R™ CRISPR crRNA product. The crRNA and tracrRNA (pur-
chased from IDT) were combined for annealing and then mixed with recombinant Cas9 protein 
(TaKaRa Shuzo Co. Ltd., Shiga, Japan) to form a complex called ribonucleoprotein (RNP). The 
final concentrations of the components in RNP were 30 μM (for crRNA/tracrRNA) and 1 mg/
ml (for Cas9 protein). GONAD was performed in superovulated B6C3ICR (hybrids between 
B6C3F1 and ICR) females (10–16 weeks of age) using RNP. Two days later, morula were col-
lected from the oviducts, fixed in 4% paraformaldehyde (PFA) for 1 day at 4°C, and then 
stained with Alexa Fluor 594 (AF594)-labeled IB4 lectin (hereafter referred to as AF594-IB4) 
for 1 day at 4°C. About 42% of morulae (5/12) tested, exhibited decreased levels of fluores-
cence after staining with AF594-IB4, as exemplified by embryo #4 (Figure 3a and b), suggest-
ing successful genome editing at the target locus, GAAT1. Notably, the residual amounts of 
maternally accumulated α-Gal epitope, appeared to be still discernible in this embryo (#4 in 
Figure 3a and b). The remaining seven embryos (including the embryos #1 to #3 in Figure 3a,b) 
Figure 3. i-GONAD-mediated production of genome-edited morulae using RNP, targeted to mouse GAAT1. A, b, 
staining of i-GONAD-treated embryos with AF594-IB4. Of the four embryos stained, embryo #4 exhibited highly reduced 
expression of α-gal epitope. Bar = 100 μm. a: Photographed under light; b: Photographed under UV and light. c, d: direct 
sequencing of PCR products derived from the i-GONAD-treated single embryo, shown in (a) and (b), and corresponding 
to the embryos #2 and #4, respectively. Boxes indicate the translation initiation codon ATG; underlines indicate PAM.
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exhibited reactivity to AF594-IB4, suggesting that they might be unedited or have mono-allelic 
mutations for GAAT1 locus. These stained embryos were individually subjected to lysis for 
genomic DNA isolation, whole genome amplification (WGA), and PCR/nested PCR for direct 
sequencing, to examine the presence of mutations in the target gene, based on our previous 
procedure for detecting mutations in the porcine GAAT1 gene [41, 42]. The primers used were 
5′-GCAAATGTGGATGCTGGGAAC-3′ (sense primer)/5′-ACAGTTTTAATGGCCATCTGG-3′ 
(reverse primer) and nested primers were 5′-TGAATCGAGCAGGTGTTTCAT-3′ (sense 
primer)/5′- AGGAACACAGGAAGACTGGAC-3′ (reverse primer). The expected size of 
PCR products was 390 bp (for 1st PCR) and 344 bp (for nested PCR). Direct sequencing of 
the PCR products demonstrated that, in the embryo showing decreased expression of α-Gal 
epitope (#4 in Figure 3a and b), there was an insertion of two nucleotides (AA) (shown by 
arrows in #4 of Figure 3c) above the protospacer adjacent motif (PAM) on the target locus, 
GAAT1. Furthermore, the sequence around the insertion site had no additional peak in the 
electrophoretogram, suggesting that #4 is a homozygous bi-allelic KO embryo. The amino 
acid sequence deduced from the nucleotide sequence of sample #4 is Met N V S R E K Stop, 
which differs from that of the authentic sequence (Met N V K G K V I L L Met L I---) and had 
premature termination of protein synthesis at seven amino acids starting from Met. On the 
other hand, embryo #2, showing normal expression of α-Gal epitope, had no mutation on 
the target region (#2 of Figure 3c). Thus, GONAD, using RNP, is useful for inducing genome 
editing within the target locus in preimplantation embryos.
6. Improved (i)-GONAD in mice
As already mentioned in Section 4, Ohtsuka et al. [35] modified GONAD as follows: 1) RNP 
was employed instead of Cas9 mRNA and gRNA; and 2) in situ genome editing within 
embryos was carried out at Day 0.7 of pregnancy. As a result, they succeeded in obtaining 
mice with insertion/deletion mutations in their genome at relatively high frequencies (~100%), 
as well as mice with large deletions in a target gene, and with knock-in of a desired sequence, 
into a target locus. Furthermore, the mutations acquired through genome editing, in the tar-
get locus, were transmitted to the next generation. Therefore, they re-named this improved 
technology “improved GONAD (i-GONAD)”. According to Ohtsuka et al. [35], i-GONAD 
is usually performed at ~16:00 from the day of the vaginal plug detection. However, this 
timing often causes inconvenience for users, such as researchers and technicians. If possible, 
experiments are done during the daytime, from 9:00 to 16:00. Since the timing for ovulation, 
and fertilization by sperm, can be shifted by changing the time of gonadotrophin administra-
tion, we first examined whether the time at which late 1-cell embryos are obtained may be 
shifted forward, by administering gonadotrophins, at an earlier time. Adult B6C3ICR females 
(10–16 weeks of age) were intraperitoneally (i.p.) injected with 5 IU of pregnant mare’s serum 
gonadotrophin (PMSG; eCG) at 11:00, followed by human chorionic gonadotrophin (hCG) 
of the same dose, 48 h later. Thereafter, the females were allowed to mate with the males. 
The next morning (~11:00 h; corresponding to Day 0.7 of pregnancy), oviduct/ovary/uterus 
were dissected and the morphology of ampulla was observed under a dissecting micro-
scope; the ampulla exhibited a tendency of shrinkage (arrow in Figure 4a). Flushing of the 
oviduct resulted in release of cumulus cell-free zygotes (Figure 4b). These findings were 
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indeed consistent with the previous findings of Ohtsuka et al. [35], who observed shrink-
age of ampulla and cumulus cell-free zygotes when females, at Day 0.7 of pregnancy, were 
inspected at ~16:00. Thus, hormone-mediated shift in timing for acquiring late 1-cell embryos 
was found to be successful.
Administration of higher dose (in this case, more than 5 IU) of gonadotrophins can induce 
superovulation, but often causes failure to deliver pups [43–45]. Some reports state that the 
administration of low-dose gonadotrophins (less than 5 IU) facilitates the ovulation of a natu-
ral number of oocytes, and successful delivery of pups [46, 47]. This evoked us to suppose that 
the use of females who have achieved pregnancy after administration of low-dose gonadotro-
phins and subsequent mating with males would be preferable for i-GONAD experiments. To 
verify this strategy, three adult B6C3ICR female mice (10~16 weeks of age) were i.p. admin-
istrated with either 5, 2, or 0.5 IU of PMSG at 11:00, followed by 5 IU of hCG, 48 h later 
(Figure 4c). In this case, light/dark cycle (7:00/19:00) in a mouse room remained unchanged. 
Thereafter, the females were mated to males (with a ratio of one female: one male). In case 
of administration of 5 IU PMSG, two of three females had vaginal plug, but failed to deliver 
their pups (Figure 4d). When these females were inspected later, one female was found to 
Figure 4. Late zygotic stage embryos can be obtained when superovulation schedule is shifted forward. a, oviduct 
dissected from a female one day after administration of superovulation-inducing hormones at 11:00. Ampulla (arrows) 
begins to show shrinkage. b, late zygotes collected from the oviduct shown in (a). Note that the isolated zygotes are 
already free from cumulus cells. Bar = 100 μm. c, a regime for performing i-GONAD towards late 1-cell embryos by 
administering gonadotrophins at an early time. d-f, birth of pups from females administered varying amounts [5 IU (d), 
2 IU (e), or 0.5 IU (f)] of PMSG. Note that females treated with low-dose PMSG (2–0.5 IU) successfully delivered normal 
number of pups, but those treated with 5 IU PMSG failed to deliver their pups.
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have two dead fetuses in its uterus. In case of administration of 2 IU PMSG, all three females 
had vaginal plug, and then delivered a total of 23 pups (average: 8) (Figure 4e). In case of 
administration of 0.5 IU PMSG, also, all three females had vaginal plug, and subsequently 
delivered a total of 25 pups (average: 8) (Figure 4f). These findings suggest that administra-
tion of low-dose PMSG at 11:00 can lead to natural delivery of normal numbers of pups.
Next, we tested whether genome-edited live mid-gestational fetuses can be obtained by 
i-GONAD, using the same conditions mentioned in Section 4. Adult B6C3ICR females 
(10–16 weeks of age) were administrated with low-dose hormones according to the regime 
shown in Figure 4c. After administration of hCG, females were mated to males. Next morning, 
Figure 5. i-GONAD-mediated production of genome-edited mid-gestational fetuses, using RNP targeted to mouse 
GAAT1. a–d, staining of i-GONAD-treated fetuses with AF594-IB4. One fetus [numbered #1; shown in (a) and (b)] was 
strongly stained by lectin (indicated by arrows), while the other fetus [numbered #2; shown in (c) and (d)] exhibited 
highly reduced expression of α-gal epitope. Bar = 500 μm. a, c: Photographed under light; b, d: Photographed under 
UV and light. c, d: Direct sequencing of PCR products derived from the i-GONAD-treated single fetuses, shown in a-d. 
Boxes indicate translation initiation codon ATG; underlines indicate PAM.
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i-GONAD, using RNP targeted to mouse GAAT1, was performed in vaginal plug-positive 
females at ~11:00. One of the four females had 14 normal and viable fetuses, when inspection was 
done 11 days after the surgery. All fetuses dissected were fixed in 4% PFA for 1 day at 4°C, and 
then stained with AF594-IB4 for 1 day at 4°C. Untreated Day 11.5 fetuses were similarly stained 
with lectin as control. Fluorescence on the surface of the stained fetuses was then inspected 
under a fluorescence microscope. Ten of the 14 fetuses showed positive and strong staining 
at the branchial arch (shown by arrows in Figure 5a and b), like the control fetus. However, 
the remaining four fetuses exhibited reduced staining for AF594-IB4, at the surface of the bran-
chial arch (Figure 5c and d). Two of these four α-Gal epitope-negative fetuses, together with 
another α-Gal epitope-positive one, were subjected to genomic DNA isolation and subsequent 
PCR analysis, as described in Section 5. Direct sequencing of PCR products demonstrated that 
the α-Gal epitope-positive samples exhibited unedited sequence of GAAT1 (Figure 5e), like an 
intact control fetus. In contrast, the samples showing reduced staining for AF594-IB4 (shown in 
Figure 5c and d) had one nucleotide (A) insertion above PAM (Figure 5f), creating an abnormal 
truncated protein with sequence MetN S Q G K S N P S Stop. Notably, the presence of a minor 
single nucleotide “C” overlapped with the inserted nucleotide “A”, suggesting that this sample 
may comprise bi-allelic KO, with different mutated nucleotides. The other α-Gal epitope-neg-
ative sample also had mutations (insertion of AA) above PAM in the exon 4 of GAAT1 (data 
not shown). From these results, i-GONAD performed in females at Day 0.7 of pregnancy, in 
which natural ovulation was induced after administration of low-dose PMSG, is proven useful 
for obtaining genome-edited animals (fetuses).
7. Conclusion
Since preimplantation embryos, including embryos at stages of fertilized eggs to cleaved 
eggs, are floating in the oviductal lumen, it is easy to manipulate them through introduc-
tion of substances (such as genome editing-related components, plasmid DNA, viral vectors 
and chemical reagents) into the oviductal lumen. Particularly, intraoviductal instillation of 
genome editing-related components and subsequent in vivo EP into an entire oviduct are now 
considered one of the most useful ways to create genome-edited animals (at least in mice 
and rats) in a convenient manner. Unfortunately, these approaches still require an expensive 
electroporator apparatus for gene delivery. Rather, in situ transfection of preimplantation 
embryos without using EP would be desirable. To achieve this, intraoviductal instillation of 
ZP-penetrating substances (as exemplified by reagents for receptor-mediated gene transfer, 
MWNTs and VisuFect), together with genome editing-related components, would be one of 
the promising approaches. If this attempt meets with success, the creation of gene-modified 
animals, including larger animals such as pigs and bovines, would be accelerated.
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